We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Needle-to-needle’: Manufacturing NeoAntigen peptides
28 Feb 2019 - Trishul Shah of PolyPeptide Laboratories looks at the prospects for individualised peptide therapeutics* […]
Read morePoster: Towards cost-efficient, scalable green SPPS
2019 - Jan Pawlas, Marika Lundqvist, Thomas Svensson, Mikael Nilsson and Jon H. Rasmussen, 25th APS – P280, 2017, Jul 2019 Read more
Read more1,4-Benzenedimethanethiol (1,4-BDMT) as a scavenger for greener peptide resin cleavages
2019 - ) J. Pawlas, T. Svensson and J. H. Rasmussen, RSC Adv., 2019, 9, 38928. Read more
Read moreSuitable solvent for cost-efficient green SPPS
10 May 2018 - TamiSolveTM NxG as a suitable solvent for cost-efficient green SPPS[…]
Read moreConsiderations for multi-product manufacturing facilities
30 Jan 2017 - Trishul Shah, Associate Director Business Development at PolyPeptide Laboratories Inc, reviews the considerations for the manufacture of active pharmaceutical ingredients at a multi-product facility.[…]
Read moreProcess validation: Manufacturing peptide APIs
28 May 2014 - Trishul Shah of the Polypeptide Group overviews the steps involved in the life-cycle approach encouraged by the US FDA in API manufacture.[…]
Read moreControl strategies for synthetic therapeutic peptide APIs – Part III: Manufacturing process considerations
2014 - I. Eggen, B. Gregg, H. Rode, A. Swietlow, M. Verlander, A. Szajek; BioPharm International, 2014 Read more
Read moreControl strategies for synthetic therapeutic peptide APIs – Part II: Raw material considerations
2014 - I. Eggen, B. Gregg, H. Rode, A. Swietlow, M. Verlander, A. Szajek; BioPharm International, May 2014 Read more
Read moreControl strategies for synthetic therapeutic peptide APIs – Part I: Analytical consideration
2014 - By Aleksander Swietlow,Harold Rode,Anita Szajek,Michael Verlander,Ivo Eggen,Brian Gregg; BioPharm International, Apr 2014 Read more
Read more